Shionogi & Co. Overview
- Year Founded
-
1878

- Status
-
Public
- Employees
-
5,489

- Stock Symbol
-
4507

- Investments
-
35
- Share Price
-
$17.36
- (As of Friday Closing)
Shionogi & Co. General Information
Description
Shionogi & Co Ltd is a specialty and generic drug manufacturing company. The company focuses on the manufacturing and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Shionogi engages in manufacturing, formulation, packaging, and analysis as part of its commercialization research that spans late stage drug discovery through commercial production. The company's research and development strategy utilizes partnership and licensing opportunities with academic constituents and venture companies.
Contact Information
Website
www.shionogi.comCorporate Office
- 1-8, Doshomachi 3-chome
- Chuo-ku
- Osaka, 541-0045
- Japan
Corporate Office
- 1-8, Doshomachi 3-chome
- Chuo-ku
- Osaka, 541-0045
- Japan
Shionogi & Co. Stock Performance
As of 13-Jun-2025, Shionogi & Co.’s stock price is $17.36. Its current market cap is $14.8B with 851M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$17.36 | $17.04 | $12.47 - $17.62 | $14.8B | 851M | 2.62M | $1.31 |
Shionogi & Co. Financials Summary
As of 31-Mar-2025, Shionogi & Co. has a trailing 12-month revenue of $2.87B.
In Thousands, USD |
TTM 31-Mar-2025 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 | FY 2023 31-Mar-2023 |
---|---|---|---|---|
EV | 9,255,922 | 9,255,922 | 11,127,279 | 9,827,051 |
Revenue | 2,874,159 | 2,874,159 | 3,011,153 | 3,151,708 |
EBITDA | 1,164,280 | 1,164,280 | 1,187,855 | 1,227,403 |
Net Income | 1,117,712 | 1,117,712 | 1,121,394 | 1,366,247 |
Total Assets | 10,260,123 | 10,260,123 | 9,361,863 | 9,844,928 |
Total Debt | 146,229 | 146,229 | 76,776 | 70,629 |
Shionogi & Co. Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Shionogi & Co. Comparisons
Industry
Financing
Details
Shionogi & Co. Competitors (11)
One of Shionogi & Co.’s 11 competitors is Astellas Pharma, a Corporation company based in Tokyo, Japan.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Astellas Pharma | Corporation | Tokyo, Japan | ||||
Kaken Pharmaceutical | Corporation | Tokyo, Japan | ||||
Biocon | Formerly PE-Backed | Bengaluru, India | ||||
SynCore Biotechnology Company | Corporation | Yilan City, Taiwan | ||||
Roche | Corporation | Basel, Switzerland |
Shionogi & Co. Patents
Shionogi & Co. Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
JP-2025038019-A | Parenteral preparations containing uracil derivatives | Pending | 09-Dec-2024 | ||
JP-2024105489-A | Method for producing condensed ring derivative with mgat2 inhibitory activity | Pending | 10-May-2024 | ||
JP-2024100975-A | Pharmaceutical composition containing dihydropyridinone derivative | Pending | 31-Jan-2024 | ||
JP-7674711-B1 | Pharmaceutical compositions containing uracil derivatives | Active | 05-Oct-2023 | ||
JP-7692546-B1 | Method for producing uracil derivatives | Active | 05-Oct-2023 |
Shionogi & Co. Signals
Shionogi & Co. Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Shionogi & Co. Investments & Acquisitions (35)
Shionogi & Co.’s most recent deal was a Merger/Acquisition with Akros Pharma for
. The deal was made on 07-May-2025.Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Akros Pharma | 07-May-2025 | Merger/Acquisition | Drug Discovery | ||
PeptiStar | 17-Apr-2025 | Later Stage VC | Drug Discovery | ||
Ping An-Shionogi | 14-Mar-2025 | Secondary Transaction - Private | Practice Management (Healthcare) | ||
Cilcare | 04-Dec-2024 | Later Stage VC | Drug Discovery | ||
AVITA | 23-Aug-2024 | Early Stage VC | Multimedia and Design Software |
Shionogi & Co. ESG
Risk Overview
Risk Rating
Updated April, 12, 2025
23.23 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,673
Rank
Percentile

Pharmaceuticals
Industry
of 844
Rank
Percentile

Pharmaceuticals
Subindustry
of 419
Rank
Percentile

Shionogi & Co. Exits (4)
Shionogi & Co.’s most recent exit was on 03-Oct-2022 from Pixie Dust Technologies. The exit was categorized as with 5 buyers.
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
Pixie Dust Technologies | 03-Oct-2022 | Completed |
|
||
Nemesis Bioscience | 15-Jun-2018 | Completed |
|
||
Pioneer (Drug Discovery) | 14-Sep-2015 | Completed |
|
||
StemRIM | 15-Dec-2014 | Later Stage VC | Completed |
Shionogi & Co. Affiliates
Subsidiaries (3)
Name | Industry | Location | Year Founded |
---|---|---|---|
Ping An-Shionogi | Shanghai, China | 2020 | |
Qpex | San Diego, CA | 2015 | |
UMN Pharma | Tokyo, Japan | 2004 |
Shionogi & Co. FAQs
-
When was Shionogi & Co. founded?
Shionogi & Co. was founded in 1878.
-
Where is Shionogi & Co. headquartered?
Shionogi & Co. is headquartered in Osaka, Japan.
-
What is the size of Shionogi & Co.?
Shionogi & Co. has 5,489 total employees.
-
What industry is Shionogi & Co. in?
Shionogi & Co.’s primary industry is Pharmaceuticals.
-
Is Shionogi & Co. a private or public company?
Shionogi & Co. is a Public company.
-
What is Shionogi & Co.’s stock symbol?
The ticker symbol for Shionogi & Co. is 4507.
-
What is the current stock price of Shionogi & Co.?
As of 13-Jun-2025 the stock price of Shionogi & Co. is $17.36.
-
What is the current market cap of Shionogi & Co.?
The current market capitalization of Shionogi & Co. is $14.8B.
-
What is Shionogi & Co.’s current revenue?
The trailing twelve month revenue for Shionogi & Co. is $2.87B.
-
Who are Shionogi & Co.’s competitors?
Astellas Pharma, Kaken Pharmaceutical, Biocon, SynCore Biotechnology Company, and Roche are some of the 11 competitors of Shionogi & Co..
-
What is Shionogi & Co.’s annual earnings per share (EPS)?
Shionogi & Co.’s EPS for 12 months was $1.31.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »